Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma by Hideo Morioka et al.
RESEARCH ARTICLE Open Access
Results of sub-analysis of a phase 2 study
on trabectedin treatment for extraskeletal
myxoid chondrosarcoma and mesenchymal
chondrosarcoma
Hideo Morioka1*, Shunji Takahashi2, Nobuhito Araki3, Hideshi Sugiura4, Takafumi Ueda5, Mitsuru Takahashi6,
Tsukasa Yonemoto7, Hiroaki Hiraga8, Toru Hiruma9, Toshiyuki Kunisada10, Akihiko Matsumine11, Michiro Susa1,
Robert Nakayama1, Kazumasa Nishimoto1, Kazutaka Kikuta1, Keisuke Horiuchi1 and Akira Kawai12
Abstract
Background: Trabectedin is reported to be particularly effective against translocation-related sarcoma. Recently, a
randomized phase 2 study in patients with translocation-related sarcomas unresponsive or intolerable to standard
chemotherapy was conducted, which showed clinical benefit of trabectedin compared with best supportive
care (BSC). Extraskeletal myxoid chondrosarcoma (EMCS) and Mesenchymal chondrosarcoma (MCS) are very rare
malignant soft tissue sarcomas, and are associated with translocations resulting in fusion genes. In addition, the
previous in vivo data showed that trabectedin affect tumor necrosis and reduction in vascularization in a xenograft
model of a human high-grade chondrosarcoma. The aim of the present analysis was to clarify the efficacy of
trabectedin for EMCS and MCS subjects in the randomized phase 2 study.
Methods: Five subjects with EMCS and MCS received trabectedin treatment in the randomized phase 2 study.
Three MCS subjects were allocated to the BSC group. Objective response and progression-free survival (PFS) were
assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by central radiology
imaging review.
Results: The median follow-up time of the randomized phase 2 study was 22.7 months, and one subject with MCS was
still receiving trabectedin treatment at the final data cutoff. The median PFS was 12.5 months (95 % CI: 7.4–not reached)
in the trabectedin group, while 1.0 months (95 % CI: 0.3–1.0 months) in MCS subjects of the BSC group. The six-month
progression-free rate was 100 % in the trabectedin group. One subject with MCS showed partial response, and the others
in the trabectedin group showed stable disease. Overall survival of EMCS and MCS subjects was 26.4 months (range, 10.
4–26.4 months) in the trabectedin group. At the final data cutoff, two of five subjects were still alive.
Conclusions: This sub-analysis shows that trabectedin is effective for patients with EMCS and MCS compared with BSC.
The efficacy results were better than previously reported data of TRS. These facts suggest that trabectedin become an
important choice of treatment for patients with advanced EMCS or MCS who failed or were intolerable to standard
chemotherapy.
Trial registration: The randomized phase 2 study is registered with the Japan Pharmaceutical Information Center,
number JapicCTI-121850 (May 31, 2012).
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Background
Trabectedin is a marine-derived antitumor agent, ini-
tially isolated from the marine ascidian (Ecteinascidia
turbinata) and currently produced synthetically. In 2007,
trabectedin 1.5 mg/m2 as a single infusion lasting 24 h
every 3 weeks was approved by the European Medicines
Agency (EMA) for treatment of advanced soft tissue sar-
comas in adults that had become unresponsive to
anthracyclines and ifosfamide or when unsuited to re-
ceive these agents. It is currently in widespread use in
Europe as a 2nd- or 3rd-line chemotherapeutic agent for
the treatment of advanced soft tissue sarcoma. The anti-
tumor mechanism of trabectedin is known to consist of
selectively binding to the minor groove of DNA, and
then interacting with the DNA excision and repair
mechanism and a transcription inhibiting action, result-
ing in inhibition of cell division and induction of apop-
tosis and antiangiogenesis [1]. Trabectedin also
interferes with the transcription of the oncogenic fusion
proteins of translocation-related sarcomas (TRS) [2, 3].
The fusion proteins which were generated by chromo-
some translocation cause to change of phenotypic prop-
erties in cell to contribute to the tumorigenic pathway
[4].
Recent clinical data showed specifically effectiveness of
trabectedin against TRS; retrospective analysis of eight
clinical studies reported encouraging disease control of
trabectedin in TRS patients [5]. Based on this informa-
tion, a randomized controlled phase 2 study of trabecte-
din 1.2 mg/m2 in patients with TRS who had failed or
had been intolerable to standard chemotherapy was con-
ducted in Japan. The overall median progression-free
survival (PFS) of the 73 subjects with TRS in the ran-
domized phase 2 study was 5.6 months (95 % CI: 4.1–
7.5) in the trabectedin group and 0.9 months (95 % CI:
0.7–1.0) in the best supportive care (BSC) group, which
showed that PFS was significantly prolonged in the tra-
bectedin group in comparison with the BSC group [6].
Extraskeletal myxoid chondrosarcoma (EMCS) and
Mesenchymal chondrosarcoma (MCS) are very rare ma-
lignant soft tissue sarcomas. Recent cytogenetic and mo-
lecular genetic studies of EMCS have found reciprocal
translocations, typically t(9;22)(q22;q12.2), resulting in
fusion of EWSR1 to NR4A3 [7, 8]. MCS is morphologic-
ally characterized by a biphasic pattern of undifferenti-
ated round cells and islands of hyaline cartilage.
Recently, the HEY1-NCOA2 fusion gene has been also
reported in MCS [9].
In addition, previous report shows that trabectedin affects
tumor necrosis and reduction in vascularization in a xeno-
graft model of a human high-grade chondrosarcoma [10],
which suggests that trabectedin shows particularly high effi-
cacy in EMCS and MCS because their cells are histopatho-
logically similar to the human chondrosarcoma cell line.
In the present analysis, we assessed the efficacy of tra-
bectedin especially against the very rare histological
types EMCS and MCS in the above-described random-
ized phase 2 study.
Methods
Patients
As the subjects of this sub-analysis, we adopted two
EMCS subjects and three MCS subjects who had been
allocated to the trabectedin group and three MCS sub-
jects who had been allocated to the BSC group in the
randomized phase 2 study. The inclusion and exclusion
criteria of the randomized phase 2 study have been pre-
viously described [6]. In brief, eligible patients were
pathologically diagnosed as a subtype of TRS (myxoid/
round cell liposarcoma, synovial sarcoma, alveolar
rhabdomyosarcoma, extraskeletal Ewing sarcoma/primi-
tive neuroectodermal tumor, dermatofibrosarcoma pro-
tuberans, low grade fibromyxoid sarcoma, alveolar soft
part sarcoma, clear cell sarcoma, angiomatoid fibrous
histiocytoma, desmoplastic small round cell tumor, giant
cell fibroblastoma, endometrial stromal sarcoma, EMCS,
and MCS); unresponsive or intolerable to the standard
chemotherapy regimens; receiving no more than four
prior chemotherapy regimens; disease progression ac-
cording to the Response Evaluation Criteria in Solid Tu-
mors (RECIST) version 1.1 confirmed by imaging during
the 14 days before the enrollment, compared with the
assessment performed during the previous 6 months.
The randomized phase 2 study was approved by the
institutional review board at each institution. All partici-
pants gave written informed consent before the initiation
of the study, which included consent to publish the re-
sults of their data. The randomized phase 2 study was
conducted in accordance with the ethical principles ori-
ginating in or derived from the Declaration of Helsinki,
International Conference on Harmonization Good Clin-
ical Practice Guidelines, and locally applicable laws and
regulations. Trabectedin was supplied by Taiho Pharma-
ceutical Co., Ltd. (Tokyo, Japan).
Treatment and assessments
Trabectedin was administered in a standard starting
dose of 1.2 mg/m2 as a 24-hour continuous intravenous
infusion via a central vein on day 1. Each treatment cycle
consists of 21 days. The 20-day cycle interval could be
extended up to 42 days when adverse events occurred.
Dose reduction was allowed in case of grade 3 or 4 ad-
verse events including thrombocytopenia < 25,000/μL,
neutropenia < 500/μL with fever and neutropenia < 500/
μL persistent for at least 6 days. The study treatment
was repeated until disease progression, unmanageable
toxicity, subject refusal, or delay for >21 days (one cycle)
occurred due to toxicity. In the BSC group, subjects
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underwent BSC to relieve symptoms and improve QOL;
anticancer therapies were prohibited. Tumor assessment
by CT or MRI was repeated at weeks 4, 8, 12, 18, and
24, and every 8 weeks thereafter.
Objective response and PFS were assessed according
to the RECIST version 1.1 by central radiology imaging
review.
The cutoff date for the final data of the randomized
phase 2 study was March 2015.
Results
Between July 11, 2012 and Jan 20, 2014, 76 patients with
TRS were enrolled in the randomized phase 2 study, and
the full analysis set consisted of 73 subjects. The number
of subjects with EMCS and MCS was 2 (2.7 %) and 6
(8.2 %), respectively. Five subjects with EMCS and MCS
were allocated to the trabectedin group, and 3 subjects
with MCS were allocated to the BSC group. Clinical infor-
mation of these subjects is presented in Table 1. In the five
subjects of the trabectedin group, the median total num-
ber of trabectedin cycles was 10.0 (range, 8–22). The me-
dian treatment duration from the first administration was
11.7 months (range, 8.9–22.8). Cycle interval of 20 days
was extended in all of five subjects, and the major reasons
for extension were neutropenia and thrombocytopenia.
The median cycle interval was 34.0 days (range, 21–47).
In one subject (subject No. 1) the dose of trabectedin was
reduced to 1.0 mg/m2 in cycle 3 because of adverse event
(creatinine phosphokinase increased).
Median follow-up time of the randomized phase 2
study was 22.7 months, and 1 subject with MCS was still
receiving treatment at the final data cutoff. The median
PFS of the subjects with EMCS and MCS was
12.5 months (95 % CI: 7.4–not reached) in the trabecte-
din group, while 1.0 months (95 % CI: 0.3–1.0 months)
in MCS subjects of the BSC group (Table 2, Fig. 1). The
six-month progression-free rate (PFR) was 100 % in the
trabectedin group. The best change in sum of the diam-
eter (%) was ranged from 1 % to −58 %. One subject
with MCS (subject No. 3) who received trabectedin
treatment for more than 2 years showed partial response
(PR). The other subjects in the trabectedin group (two
with EMCS and two with MCS) showed stable disease
(SD). Progressive disease (PD) was not observed as best
response in the trabectedin group. Median overall sur-
vival (OS) of EMCS and MCS subjects in the trabectedin
group was 26.4 months (range, 10.4–26.4 months), and
at the final data cutoff, two subjects were still alive.
Representative clinical course of both EMCS (subject
No. 2) and MCS (subject No. 3) cases with trabectedin
treatment are shown in Figs. 2 and 3. Subject No. 2 re-
ceived eight trabectedin cycles for 8.9 months, showing
27 % shrinkage at 4 months after enrollment. Subject
No. 3 had a target lesion of 11 mm in lung at baseline
which had increased until the subject started trabectedin
treatment. Subject No. 3 received 22 trabectedin cycles
over 22.8 months, showing increasing tumor size during
first 3 months, and then shrinking to 58 % at 11.0 months
after enrollment. Of another three subjects, two showed
the best shrinkage within first 2 months, and their lesions
thereafter gradually grew. The worst change in the diam-
eter of their lesions was ranged from 9.2 to 39.5 %.


























1 50- < 60 0 EMCS lower limbs resected 132.8 94.2 8.7 (IE)
2 60- < 70 1 EMCS lower limbs resected 38.4 4.3 1.1 (doxorubicin)
3 <40 0 MCS neck conserved 11.3 63.0 NA (neoadjuvant chemotherapy)
4 <40 1 MCS basal meninges resected 162.3 82.6 3.7 (doxorubicin)
5 <40 1 MCS neck resected 57.3 145.6 NA (neoadjuvant chemotherapy)
Best supportive care group
6 <40 1 MCS face conserved 136.8 116.2 7.0 (doxorubicin and cisplatin)
7 <40 0 MCS pleura resected 94.6 2.5 0.7 (VDC)
8 <40 1 MCS retroperi-toneum resected 209.3 13.4 NA (neoadjuvant chemotherapy)
MCS Mesenchymal chondrosarcoma, EMCS Extraskeletal myxoid chondrosarcoma, PS performance status, NA not applicable, IE ifosfamide and etoposide, VDC
vincristine, doxorubicin and cyclophosphamide
aEastern Cooperative Oncology Group (ECOG) performance status
bAssessed by central radiology imaging review
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No subjects withdrew from the study due to toxicity,
and no deaths were assessed as drug-related. Adverse
drug reactions in the trabectedin group are shown in
Table 3.
Discussion
EMCS is a rare soft tissue sarcoma that accounts for less
than 3 % of all soft tissue sarcomas, which was first re-
ported by Enzinger in 1972. EMCS contains an abundant
mucinous stroma in which malignant chondroblast-like
tumor cells grow in a lobulated manner. No clear differen-
tiation by the tumor cells into cartilage is seen, and histo-
logically EMCS is classified as soft tissue sarcoma with no
clear differentiation tendencies. A high rate of characteris-
tic chromosome translocations, i.e., t(9;22)(q22;q12) and
t(9;17)(q22;q11), and resulting fused genes, i.e., EWSR1-
NR4A3 and TAF15-NR4A3, are seen in the tumors. EMCS
usually grows slowly, but the oncologic properties are
often unclear. The basic treatment of EMCS is wide resec-
tion, and the benefit of chemotherapy or radiotherapy has


















1 EMCS 15.6 13.0 SD −1 26.4 progression
2 EMCS 8.9 7.4 SD −27 10.4 progression
3 MCS 22.8 22.2* PR −58 23.0* (continued)c
4 MCS 10.8 7.5 SD 1 19.2* progression
5 MCS 11.7 12.5 SD −1 12.5 subject
withdrawald
Best supportive care group
6 MCS 0.5 0.5* NE −2 24.2 progression
7 MCS 0.3 0.3 PD 12 6.4 progression
8 MCS 1.0 1.0 PD 46 3.4 progression
MCS Mesenchymal chondrosarcoma, EMCS Extraskeletal myxoid chondrosarcoma, PFS progression-free survival, PR partial response, SD stable disease, NE not eva-
luable, PD progressive disease
* Censored observation
aAssessed by central radiology imaging review
bThe best change in sum of the diameter of target lesions from baseline
cParticipated in another study for continuing trabectedin treatment after termination of the randomized phase 2 study


























Number of patient at risk 
Trabectedin 5 5 5 3 3 1 1 1 
Best supportive care 3 - - - - - - -
Fig. 1 Kaplan-Meier plot of progression-free survival. Progression-free survival of five patients with EMCS and MCS randomized to the trabectedin
group (−) and three patients with MCS randomized to the BSC group (−−−)
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never been established. A report by Ogura et al. [11]
stated that ifosfamide-containing chemotherapy was per-
formed in four high-grade EMCS cases, and their re-
sponses were not available (NA) in one case, SD in one
case, and PD in two cases. The efficacy of the chemother-
apy was reported as inadequate.
MCS, on the other hand, is a subtype of chondrosar-
coma that consists of proliferation of poorly differenti-
ated small round cells and well differentiated cartilage
tissue. In recent years, a tumor-specific fusion gene
HEY1-NCOA2 that occurs as a result of a chromosome
translocation was identified by Wang et al. [9]. The lar-
gest proportion of MCS, over 70 %, arises from bone,
and less than 30 % originate in soft tissue. However,
MCS originated in soft tissue is said to be more than re-
ported, in the following respects. First, it is sometimes
difficult to determine whether the origin of an MCS of
the spine, etc., is bone or dura mater. Second, whereas
many MCSs are of dural origin, some dural origin MCS
may have been included among those of bony origin.
Not surprisingly, the treatment of first choice for MCS
is wide resection. Although occasional cases have shown
disease control by chemotherapy and/or radiotherapy,
no consensus about use of chemotherapy or radiother-
apy has been reached to date.
In the randomized phase 2 study on which the present
analysis was based, trabectedin was introduced into five
subjects with advanced EMCS and MCS. All of five sub-
jects showed improved disease control, in contrast with
the three subjects with MCS in the BSC group. It should
be noted that long-term disease control was observed in
the all subjects with EMCS and MCS in the trabectedin
group. Moreover, the PFS of EMCS and MCS in the tra-
bectedin group seemed to be better than that of myxoid
liposarcoma, which has been demonstrated to be highly
responsive to trabectedin [5, 12]. Le Cesne et al. [13]
reported that median PFS and OS of chondrosarcoma
were 6.267 months (95 % CI: 0.000–15.935) and
21.400 months (95 % CI: 9.641–33.159), which seem to
be slightly longer than those of liposarcoma [median
Subtype Age PS Primary lesion Anamnesis Prior therapies
EMCS 60- < 70 1 Lower limbs Heart failure, hepatic dysfunction Resection of primary lesion
Radiotherapy 
Resection of metastasis in neck
Doxorubicin (2 cycles)
Complications Findings at baseline Target lesions at enrollment

































Fig. 2 Clinical course of subject No.2. CT images of target lesions in lung at (a, b) enrollment in the study, (c, d) 4.0 months after enrollment
(27 % decrease in sum of diameters), (e, f) 9.2 months after enrollment (50 % increase in sum of diameters). EMCS: Extraskeletal myxoid
chondrosarcoma. ▼: Administration of trabectedin. —: Borderline of 30 % decrease in sum of diameters
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PFS; 6.067 months (95 % CI: 4.488–7.645), median OS;
15.000 months (95 % CI: 11.033–18.967)]. Our data in
EMCS and MCS showed similar PFS and OS.
We observed anti-tumor effect (PR or SD) in all sub-
jects in the trabectedin group. One subject with MCS
showed promising response, with tumors shrinking more
than 50 %.
Le Cesne et al. [5] retrospectively investigated the effi-
cacy of trabectedin in 81 subjects with TRS (synovial sar-
coma, myxoid-round cell liposarcoma, alveolar soft part
sarcoma, endometrial stromal sarcoma, and clear cell
sarcoma, not including EMCS and MCS). The results
showed median PFS was 4.1 months (95 % CI: 2.8–6.1),
the six-month PFR was 40 %, and the OS of TRS was
17.4 months (95 % CI: 11.1–23.2). The present analysis
seems to show better results.
In research in vitro, trabectedin has been reported to
inhibit the transcription factor function of fused proteins
produced as a result of the chromosome translocations
in some human bone and soft tissue sarcoma cell lines
that have a chromosome translocation [2, 3]. This
appears to be one of the mechanisms by which trabecte-
din exhibits a strong antitumor effect against soft tissue
sarcomas that have chromosome translocations.
There are limited data about the efficacy of chemotherapy
in patients with EMCS or MCS, because EMCS and MCS
are very rare tumors, and no consensus has been reached
in regard to the efficacy of existing chemotherapy for either
of these tumors. Additionally, the starting trabectedin dose
of 1.2 mg/m2 used in the present analysis of the phase 2
study was based on the phase 1 study [14], which is lower
than the approved initial dose of 1.5 mg/m2, and corre-
sponds to the approved first reduction dose in case of tox-
icity for the treatment of advanced STS in the European
Union. Limitations of our results include the small sample
size and resultant difficulty to generalize. Our findings sug-
gest that it is necessary to evaluate efficacy of trabectedin
for more patients with EMCS and MCS.
Conclusions
In conclusion, this sub-analysis shows that trabectedin is
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Subtype Age PS Primary lesion Anamnesis Prior therapies
MCS < 40 0 Neck None
Preoperative chemotherapy (VDC, IE)
Resection of primary lesion in spine C1-C2
Radiotherapy
Resection of metastasis in spine C5-C7
Complications Findings at baseline
Target lesions at 
enrollment
Allergic rhinitis, 
aeration disorder of right ear




























Fig. 3 Clinical course of subject No.3. CT images of target lesion in lung at (a) enrollment in the study, (b) 11.1 months after enrollment (58 %
decrease in sum of diameters), (c) 22.5 months after enrollment (46 % increase in sum of diameters). MCS: Mesenchymal chondrosarcoma, VDC:
vincristine, doxorubicin and cyclophosphamide, IE: ifosfamide and etoposide.▼: Administration of trabectedin. —: Borderline of 30 % decrease in
sum of diameters
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with BSC. The efficacy results were better than previ-
ously reported data of TRS. In the study on which this
analysis was based, trabectedin was introduced into sub-
jects with advanced EMCS and MCS, and showed long-
term disease control in all the subjects. Tumor shrinking
effects were also observed, and one subject who showed
PR has undergone long-term treatment. These facts sug-
gest that trabectedin become an important choice of
treatment for patients with advanced EMCS and MCS
who failed or intolerable to standard chemotherapy.
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